Keyword: Shanghai Fosun Pharmaceutical Group

Daiichi rejigs management; China approves its first biosimilar; Sinovac uses a poison pill to fend off an investor takeover.

Chinese authorities have approved Fosun subsidiary Henlius' Rituxan copycat, the country's first biosimilar.

The number of flu shots that passed Chinese regulators so far this season has fallen about 19%, leaving the country short on needed supplies.

Aurobindo buys parts of Sandoz for $1B; an ex-GSK scientist admits to stealing trade secrets; Lilly and Chi-Med's Chinese-made drug makes history.

In probably a new drug scandal from China, self-proclaimed employees alleged that a Fosun unit faked production and testing records.

China's WuXi Biologics and Sinobioway will build biologics facilities; Takeda expects Velcade freefall and looks to offload R&D assets to cut costs.

The combined value of those assets on the for-sale list, which include Novartis' U.S. generics dermatology business, could reach $2 billion.

Not all Big Pharma's businesses in emerging markets are doing so well, Fosun is buying a smaller stake in Gland, Taiho and Arcus ink cancer option deal.

Fosun Pharma has cut back its offer for Gland Pharma just enough to circumvent the Indian government’s scrutiny.

Samsung inked a novel drug R&D pact with Takeda, GSK China partnered with Alibaba on HPV vaccination, Gland is revising its M&A deal with Fosun.